Recent Posts on This Topic | See All >
InNexus Biotechnology awarded federal grantTags: cancer
[Source: Finacial Times] - InNexus Biotechnology Inc., a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company’s development of DXL™ anti-cancer antibodies.
For more information: InNexus Biotechnology Awarded Federal Grant
“Arizona’s Bioscience Roadmap 2014-2025: Advancing the Biosciences and Improving Health Outcomes,” is available along with its supplement, “Summary of Goals, Strategies, and Potential Actions.” The updated Roadmap provides a long-term strategy for Arizona to achieve bioscience success over the next decade. Also, discover The State of Bioscience.